Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

CAR T-Cell Therapy Approved for Large B-Cell Lymphoma

The U.S. Food and Drug Administration (FDA) has approved the gene-edited autologous chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) for adult patients...
WIB_icon

Avelumab Shows Clinical Activity in Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma

Avelumab is clinically active in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (ENKTL), although researchers observed a lower-than-expected response rate, according to...

The Future of Chronic Graft-Versus-Host Disease

An Update From the 3rd NIH Chronic GVHD Consensus Conference In this edition, Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and...
WIB_icon

CONTRALTO: Evaluating a Chemotherapy-Free Approach With Venetoclax in Relapsed/Refractory Follicular Lymphoma

A chemotherapy-free approach comprising venetoclax and rituximab (VEN+R) showed modest efficacy in the treatment of patients with relapsed/refractory follicular lymphoma and was outperformed by...

FDA Accepts Investigational New Drug Application for PBCAR19B in Non-Hodgkin Lymphoma

The FDA has cleared Precision BioSciences’ Investigational New Drug application for its chimeric antigen receptor (CAR) T-cell therapy PBCAR19B. The company will initiate a...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
On location

BTK Inhibitor LOXO-305 Shows Promise in Previously Treated Mantle Cell Lymphoma

In the phase I/II BRUIN trial that included patients with previously treated B-cell malignancies – particularly mantle cell lymphoma (MCL) – treatment with the...
On location

Does High-Dose Methotrexate Protect the Central Nervous System in High-Risk DLBCL?

A retrospective study found that treatment with high-dose methotrexate did not lower the risk of central nervous system (CNS) relapse in patients with high-risk...
WIB_icon

Azacitidine and Romidepsin Combination Shows High Activity in Peripheral T-Cell Lymphoma

A combination regimen consisting of oral azacitidine and romidepsin was highly active in patients with peripheral T-cell lymphoma (PTCL), particularly in previously untreated patients...
On location

Burkitt Lymphoma IPI Validated Across Patients from Four Continents

Researchers have created a prognostic index specific to Burkitt lymphoma (BL) that will allow for simplified stratification and comparison of risk distribution in geographically...
Advertisement

Current Issue

February 2021 Volume 7 Issue 3

This issue explores common pitfalls for doctors considering careers outside of patient care, new treatments for porphyrias, and more.

Block title